| Product Unit Size | Cost | Quantity | Stock |
|---|
Dexrazoxane is an iron chelator that exhibits cardioprotective, antioxidative, pro-angiogenic, and anti-parasitic activities. Dexrazoxane decreases superoxide formation and prevents anthracycline-induced cardiotoxicity. In animal models of myocardial infarction, dexrazoxane decreases infarct size, increases capillary density, and improves cardiac function. Additionally, this compound displays antimalarial benefit, inhibiting growth of Plasmodium.
| Cas No. | 24584-09-6 |
|---|---|
| Purity | ≥98% |
| Formula | C11H6N4O4 |
| Formula Wt. | 268.27 |
| IUPAC Name | 4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione |
| Solubility | 10mg/mL in DMSO 5mg/mL in DMF |
| Appearance | White to off white powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Doroshow JH. Dexrazoxane for the prevention of cardiac toxicity and treatment of extravasation injury from the anthracycline antibiotics. Curr Pharm Biotechnol. 2012 Aug;13(10):1949-56. PMID: 22352729.
Zhou L, Sung RY, Li K, et al. Cardioprotective effect of dexrazoxane in a rat model of myocardial infarction: anti-apoptosis and promoting angiogenesis. Int J Cardiol. 2011 Oct 20;152(2):196-201. PMID: 20692056.
Jones RL. Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity. Expert Rev Cardiovasc Ther. 2008 Nov;6(10):1311-7. PMID: 19018683.
Loyevsky M, Sacci JB Jr, Boehme P, et al. Plasmodium falciparum and Plasmodium yoelii: effect of the iron chelation prodrug dexrazoxane on in vitro cultures. Exp Parasitol. 1999 Feb;91(2):105-14. PMID: 9990337.